These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18836491)

  • 1. Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?
    Singh V; Krishnamurthy J; Duffey S; Meagher R; Villa M; Monreal J; Evens A; Frankfurt O; Altman J; Gordon L; Tallman M; Williams S; Winter J; Singhal S; Mehta J
    Bone Marrow Transplant; 2009 Feb; 43(4):301-5. PubMed ID: 18836491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss.
    Maclean PS; Parker AN; McQuaker IG; Clark AD; Farrell E; Douglas KW
    Bone Marrow Transplant; 2007 Oct; 40(7):665-9. PubMed ID: 17646841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation.
    Hicks C; Trickett A; Kwan YL; Ramanathan S
    Ann Hematol; 2012 Nov; 91(11):1795-801. PubMed ID: 22836946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?
    Ali MY; Oyama Y; Monreal J; Winter JN; Tallman MS; Williams SF; Singhal S; Gordon LI; Mehta J
    Bone Marrow Transplant; 2003 May; 31(10):861-4. PubMed ID: 12748662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?
    Cilley J; Rihn C; Monreal J; Gordon LI; Singhal S; Tallman M; Williams S; Winter J; Mehta J
    Bone Marrow Transplant; 2004 Jan; 33(2):161-4. PubMed ID: 14647242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ideal Body Weight Is Useful For Predicting Neutrophil Engraftment and Platelet Recovery for Overweight and Obese Recipients in Single-Unit Cord Blood Transplantation.
    Okada Y; Nakasone H; Konuma T; Uchida N; Tanaka M; Sugio Y; Aotsuka N; Nishijima A; Katsuoka Y; Ara T; Ota S; Onizuka M; Sawa M; Kimura T; Fukuda T; Atsuta Y; Kanda J; Kimura F
    Transplant Cell Ther; 2022 Aug; 28(8):504.e1-504.e7. PubMed ID: 35577325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation.
    Singhal S; Gordon LI; Tallman MS; Winter JN; Evens AM; Frankfurt O; Williams SF; Grinblatt D; Kaminer L; Meagher R; Mehta J
    Bone Marrow Transplant; 2006 Mar; 37(6):553-7. PubMed ID: 16444282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight.
    Waples JM; Moreb JS; Sugrue M; Belanger G; Kubilis P; Lynch JW; Gian V; Weeks F; Wingard J
    Bone Marrow Transplant; 1999 May; 23(9):867-73. PubMed ID: 10338040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to calculate the quantity of CD34+ cells infused? A single center cohort study based on actual, ideal or adjusted ideal body weight.
    Topcuoglu P; Akcaglayan Soydan E; Ekiz F; Ayyildiz E; Dalva K; Ozcan M; Arslan O; Arat M; Ilhan O
    Transfus Apher Sci; 2007 Jun; 36(3):275-80. PubMed ID: 17569588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
    Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
    Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryopreserved CD34
    Konuma T; Kato S; Oiwa-Monna M; Tanoue S; Ogawa M; Isobe M; Tojo A; Takahashi S
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1142-1150. PubMed ID: 28390987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
    Hicks C; Isaacs A; Wong R; Chong BH
    Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
    Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
    Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen.
    Morris CL; Siegel E; Barlogie B; Cottler-Fox M; Lin P; Fassas A; Zangari M; Anaissie E; Tricot G
    Br J Haematol; 2003 Feb; 120(3):413-23. PubMed ID: 12580955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
    Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
    Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
    Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
    J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells.
    Johnson RJ; Owen RG; Smith GM; Child JA; Galvin M; Newton LJ; Rawstron A; Major K; Woodhead V; Robinson F; Jack A; Morgan GJ
    Bone Marrow Transplant; 1996 May; 17(5):723-7. PubMed ID: 8733688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.